Second, due to the small proportion of HER2+ breast cancer patients in all breast cancer, the enrolled population was limited, combined with the high heterogeneity of HER2+ breast cancer, resulting in insufficient numbers of patients in some subtypes or with certain DMS to produce significant results. The gene discussed is ERBB2; the disease is breast cancer.